Fisetin and rutin as 3C protease inhibitors of enterovirus A71

Journal of Virological Methods - Tập 182 - Trang 93-98 - 2012
Ying-Ju Lin1,2, Yi-Chih Chang3, Nai-Wan Hsiao4, Jing-Ling Hsieh3,4, Ching-Ying Wang5, Szu-Hao Kung6, Fuu-Jen Tsai1,2, Yu-Ching Lan7, Cheng-Wen Lin3,8
1Department of Medical Research, China Medical University Hospital, Taichung, Taiwan
2School of Chinese Medicine, China Medical University, Taichung, Taiwan
3Department of Medical Laboratory Science and Biotechnology, China Medical University, Taichung, Taiwan
4Institute of Biotechnology, National Changhua University of Education, Changhua, Taiwan
5School of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan
6Department of Biotechnology and Laboratory Science in Medicine, National Yang-Ming University, Taipei, Taiwan
7Department of Health Risk Management, China Medical University, Taichung 404, Taiwan
8Department of Biotechnology, College of Health Science, Asia University, Wufeng, Taichung, Taiwan

Tài liệu tham khảo

Benavente, 2008, Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity, J. Agric. Food Chem., 56, 6185, 10.1021/jf8006568 Binford, 2005, Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor, Antimicrob. Agents Chemother., 49, 619, 10.1128/AAC.49.2.619-626.2005 Binford, 2007, In vitro resistance study of rupintrivir, a novel inhibitor of human rhinovirus 3C protease, Antimicrob. Agents Chemother., 51, 4366, 10.1128/AAC.00905-07 Castrillo, 1986, 3-Methylquercetin is a potent and selective inhibitor of poliovirus RNA synthesis, Virology, 152, 219, 10.1016/0042-6822(86)90386-7 Chang, 1999, Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease, Lancet, 354, 1682, 10.1016/S0140-6736(99)04434-7 Chen, 2008, Development of antiviral agents for enteroviruses, J. Antimicrob. Chemother., 62, 1169, 10.1093/jac/dkn424 Chen, 2009, Novel antiviral agent DTriP-22 targets RNA-dependent RNA polymerase of enterovirus 71, Antimicrob. Agents Chemother., 53, 2740, 10.1128/AAC.00101-09 Chu, 1992, Inhibitory effects of flavonoids on Moloney murine leukemia virus reverse transcriptase activity, J. Nat. Prod., 55, 179, 10.1021/np50080a005 Conti, 1992, Mechanism of action of the antirhinovirus flavanoid 4′,6-dicyanoflavan, Antimicrob. Agents Chemother., 36, 95, 10.1128/AAC.36.1.95 Conti, 1990, Activities and mechanisms of action of halogen-substituted flavanoids against poliovirus type 2 infection in vitro, Antimicrob. Agents Chemother., 34, 460, 10.1128/AAC.34.3.460 Dragovich, 1998, Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studies, J. Med. Chem., 41, 2819, 10.1021/jm9800696 Genovese, 1995, Effect of chloro-, cyano-, and amidino-substituted flavanoids on enterovirus infection in vitro, Antiviral Res., 27, 123, 10.1016/0166-3542(95)00088-4 Ho, 1999, An epidemic of enterovirus 71 infection in Taiwan. Taiwan Enterovirus Epidemic Working Group, N. Engl. J. Med., 341, 929, 10.1056/NEJM199909233411301 Huang, 1999, Neurologic complications in children with enterovirus 71 infection, N. Engl. J. Med., 341, 936, 10.1056/NEJM199909233411302 Hung, 2011, Synergistic inhibition of enterovirus 71 replication by interferon and rupintrivir, J. Infect. Dis., 203, 1784, 10.1093/infdis/jir174 Kuo, 2008, Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents, Bioorg. Med. Chem., 16, 7388, 10.1016/j.bmc.2008.06.015 Lei, 2011, Cleavage of the adaptor protein TRIF by enterovirus 71 3C inhibits antiviral responses mediated by Toll-like receptor 3, J. Virol., 85, 8811, 10.1128/JVI.00447-11 Lin, 2003, Enterovirus 71 outbreaks, Taiwan: occurrence and recognition, Emerg. Infect. Dis., 9, 291, 10.3201/eid0903.020285 Lin, 2006, Evolution of EV-A71 genogroup in Taiwan from 1998 to 2005: an emerging of subgenogroup C4 of EV-A71, J. Med. Virol., 78, 254, 10.1002/jmv.20534 Lu, 2011, Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design, J. Virol., 85, 10319, 10.1128/JVI.00787-11 Lyu, 2005, Antiherpetic activities of flavonoids against herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) in vitro, Arch. Pharm. Res., 28, 1293, 10.1007/BF02978215 Manthey, 2001, Biological properties of citrus flavonoids pertaining to cancer and inflammation, Curr. Med. Chem., 8, 135, 10.2174/0929867013373723 Matthews, 1999, Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes, Proc. Natl. Acad. Sci. U.S.A., 96, 11000, 10.1073/pnas.96.20.11000 Mizuta, 2009, Cross-antigenicity among EV-A71 strains from different genogroups isolated in Yamagata, Japan, between 1990 and 2007, Vaccine, 27, 3153, 10.1016/j.vaccine.2009.03.060 Orhan, 2010, Antibacterial, antifungal, and antiviral activities of some flavonoids, Microbiol. Res., 165, 496, 10.1016/j.micres.2009.09.002 Panasiak, 1989, Influence of flavonoids on combined experimental infections with EMC virus and Staphylococcus aureus in mice, Acta Microbiol. Pol., 38, 185 Patick, 1999, In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease, Antimicrob. Agents Chemother., 43, 2444, 10.1128/AAC.43.10.2444 Pallansch, 2007, Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, 839 Pawlotsky, 2007, The hepatitis C virus life cycle as a target for new antiviral therapies, Gastroenterology, 132, 1979, 10.1053/j.gastro.2007.03.116 Rivera, 2008, Modulation of enteroviral proteinase cleavage of poly(A)-binding protein (PABP) by conformation and PABP-associated factors, Virology, 375, 59, 10.1016/j.virol.2008.02.002 Salvati, 2004, Mechanism of action at the molecular level of the antiviral drug 3(2H)-isoflavene against type 2 poliovirus, Antimicrob. Agents Chemother., 48, 2233, 10.1128/AAC.48.6.2233-2243.2004 Singh, 2002, Complete sequence analyses of enterovirus 71 strains from fatal and non-fatal cases of the hand, foot and mouth disease outbreak in Singapore, Microbiol. Immunol., 46, 801, 10.1111/j.1348-0421.2002.tb02767.x Spouge, 1992, Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates, Proc. Natl. Acad. Sci. U.S.A., 89, 7581, 10.1073/pnas.89.16.7581 Tao, 2007, In vitro anti-HIV and -HSV activity and safety of sodium rutin sulfate as a microbicide candidate, Antiviral Res., 75, 227, 10.1016/j.antiviral.2007.03.008 Tsai, 2009, Real-time monitoring of human enterovirus (HEV)-infected cells and anti-HEV 3C protease potency by fluorescence resonance energy transfer, Antimicrob. Agents Chemother., 53, 748, 10.1128/AAC.00841-08 Weng, 2009, Enterovirus 71 3C protease cleaves a novel target CstF-64 and inhibits cellular polyadenylation, PLoS Pathog., 5, e1000593, 10.1371/journal.ppat.1000593 Yang, 2009, Enterovirus 71 outbreak in the People's Republic of China in 2008, J. Clin. Microbiol., 47, 2351, 10.1128/JCM.00563-09 Zuo, 2005, In vitro anti-HCV activities of Saxifraga melanocentra and its related polyphenolic compounds, Antivir. Chem. Chemother., 16, 393, 10.1177/095632020501600606